IGF::OT::IGF PHASE II TRIAL OF WEEKLY ERLOTINIB DOSING TO REDUCE DUADENAL POLYP BURDEN ASSOCIATED WITH FAMILIAL ADENOMATOUS POLYPOSIS

以前的研究发现，使用厄洛替尼与显著的十二指肠肿瘤消退有关。最近在《美国医学会杂志》上发表了一项研究；然而，有显著的不良反应限制了耐受性(即痤疮样皮疹和口腔粘膜炎)。临床前和早期临床试验数据表明，间歇性、每周一次的厄洛替尼剂量(每日剂量的7倍)保持临床疗效，不良反应较少。

Previous studies have found that the use of erlotinib is associated with marked duodenal neoplasia regression. One study was recently published in the Journal of the American Medical Association; however, there were significant adverse effects that limited tolerability (i.e. acneiform rash and oral mucositis). Preclinical and early phase clinical trial data suggest that intermittent, once weekly dosing of erlotinib (seven times the daily dose) maintains clinical efficacy with fewer adverse effects.